Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations
Mark S. Freedman, E. Ann Yeh(Hospital for Sick Children), Sarah A. Morrow(University of Calgary), Pierre Duquette(Centre Hospitalier de l’Université de Montréal), Michael C. Levin(University of Saskatchewan), Jiwon Oh(St. Michael's Hospital), Paul S. Giacomini(Montreal Neurological Institute and Hospital), Dalia Rotstein(St. Michael's Hospital), Fabrizio Giuliani(University of Alberta), Virginia Devonshire(University of British Columbia), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
April 6, 2020
Cited by 133
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k